Health Care • Biotechnology: Pharmaceutical Preparations
$18.61 ▲ +0.22
(+1.20%)
MKT CAP: $2.37B • VOL: 1.67M
52W L $17 52W H $32
ROARABLE / RQD
D- • 35/100
PIOTROSKI
1 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$16
MEDIAN
$21
MEAN
$21
HIGH
$25
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE RCUS TAPE
RCUS // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $22.52 | $21.40 | 2025-02-14 | $16.94 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $23.45 | $21.96 | 2025-02-06 | $17.49 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $21.22 | $20.47 | 2025-01-29 | $17.87 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $18.98 | — | 2025-01-17 | $18.24 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $16.38 | $17.68 | 2025-01-09 | $16.56 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $22.15 | $19.35 | 2024-12-18 | $16.19 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $18.05 | $18.80 | 2024-12-04 | $17.31 | -4.3% | 48% | C |